MiNK Therapeutics (INKT) Other financing activities (2021 - 2022)
MiNK Therapeutics (INKT) posted Other financing activities of $111.0 for Q4 2022, down 77.53% sequentially from $494.0 in Q3 2022, and down 100.0% YoY from $39.8 million in Q4 2021.
MiNK Therapeutics (INKT) Other financing activities (2021 - 2022) Analysis & Trends
MiNK Therapeutics has reported Other financing activities for 2 years, with the latest figure at $111.0 in Q4 2022.
- Quarterly Other financing activities fell 100.0% year-over-year to $111.0 in Q4 2022, while the trailing twelve-month figure through Dec 2024 was $605.0 (changed N/A YoY) and the FY2024 annual result came in at $5.8 million, changed N/A from the prior year.
- Other financing activities eased to $111.0 in Q4 2022 per INKT's latest filing, from $494.0 in the prior quarter.
- Over five years, Other financing activities peaked at $39.8 million in Q4 2021 and troughed at $111.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 111.00 |
| Dec 31, 2022 | 111.00 |
| Sep 30, 2022 | 494.00 |
| Sep 30, 2022 | 494.00 |
| Jun 30, 2022 | 301.00 |
| Jun 30, 2022 | 301.00 |
| Mar 31, 2022 | 689.00 |
| Mar 31, 2022 | 689.00 |
| Dec 31, 2021 | 39.80 Mn |
| Dec 31, 2021 | 39.80 Mn |